Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 5100 shares changing hands. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The company has a current ratio of 0.49, a quick ratio of 0.48 and a debt-to-equity ratio of -72.45. The stock has a market capitalization of C$11.87 million, a P/E ratio of -2.07 and a beta of 0.59. The company has a 50-day moving average price of C$0.07 and a 200 day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Articles
- Five stocks we like better than Hemostemix
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
